C4 Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on C4 Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how C4 Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with C4 Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
C4 Therapeutics Inc (C4 Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines through targeted protein degradation for cancer treatments. The company pipeline products include Cemsidomide, an orally bioavailable small-molecule degrader targeting IKZF1/3 for the treatment of multiple myeloma and non-hodgkin’s lymphomas; CFT8919 which treats non-small cell lung cancer; and CFT1946 targets V600 Mutant Cancers. C4 Therapeutics leverages its proprietary platform TORPEDO (target-oriented protein degrader optimizer) that designs and optimizes small-molecule medicines to address difficult-to-treat diseases. It collaborates with Roche, Biogen, Betta Pharmaceuticals, Merck, and Merck KGaA. C4 Therapeutics is headquartered in Watertown, Massachusetts, the US.
Headquarters
United States of America
Address
490 Arsenal Way, Suite 120, Watertown, Massachusetts, 02472
Website
c4therapeutics.com
Telephone
1 617 2310700
No of Employees
104
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CCCC (NASD)
Revenue (2024)
$35.9M
1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
0.3%
(2024 vs 2023)
Market Cap*
$475.4M
Net Profit Margin (2024)
XYZ
1.3%
(2024 vs 2023)
* As of and is in US$
C4 Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TORPEDO |
| CFT1946: V600 Mutant Solid Tumors | BiDAC |
| CFT8919: Non-Small Cell Lung Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into a supply agreement with Pfizer Inc. for elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific). |
| 2024 | Contracts/Agreements | In March, the company and Merck KGaA signed a license and collaboration agreement for the discovery of two targeted protein degraders against critical oncogenic proteins. |
| 2024 | Others | In January, the company completed US$25 million stock purchase agreement with a subsidiary of Betta Pharmaceuticals Co. Ltd (Betta). |
Competitor Comparison
| Key Parameters | C4 Therapeutics Inc | AstraZeneca Plc | Astellas Pharma Inc | Haisco Pharmaceutical Group Co Ltd | Arvinas Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | Japan | China | United States of America |
| City | Watertown | Cambridge | Chuo-Ku | Shannan | New Haven |
| State/Province | Massachusetts | Cambridgeshire | Tokyo | Tibet | Connecticut |
| No. of Employees | 104 | 96,100 | 13,643 | 5,597 | 246 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ronald Harold Wilfred Cooper | Chairman | Executive Board | 2024 | 63 |
| Kendra R. Adams | Chief Financial Officer; Treasurer; Head - Corporate Affairs | Senior Management | 2023 | 49 |
| Kelly A. Schick | Chief People Officer | Senior Management | 2022 | 46 |
| Leonard Reyno, M.D. | Chief Medical Officer | Senior Management | 2023 | 64 |
| Paige Mahaney, Ph.D | Chief Scientific Officer | Senior Management | 2024 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer